AngioDynamics Names Alan Panzer SVP, GM of Vascular Division

September 12, 2011 at 6:30 AM EDT

ALBANY, N.Y., Sept. 12, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, has appointed Alan Panzer, 50, as Senior Vice President and General Manager of the Company's Vascular Division, effective September 12, 2011. Mr. Panzer will report to President and CEO Joseph M. DeVivo

Mr. Panzer brings more than 20 years of industry experience to AngioDynamics. He most recently served as President & CEO of DeVilbiss Healthcare, where he successfully executed the challenging refocusing of the organization, leading to a turnaround of the company and profitability. Prior to DeVilbiss, Mr. Panzer was President of United States Surgical & Valleylab, now a business unit of Covidien, where annual revenue grew from $550 million to $1.2 billion during his tenure.

"Alan's broad executive leadership and commercial experience at multiple surgical device and vascular organizations will help our vascular division meet its full potential," said Mr. DeVivo. "Alan has proven his ability to understand customers' and patients' needs, organize to meet them, and make great inroads into new and existing markets. We are excited to have him join our team."

"AngioDynamics has sizable opportunities ahead of it, and possesses the financial flexibility and enviable pipeline to fully develop those opportunities," said Mr. Panzer. "There is a highly experienced leadership team positioned to grow the company, and I am eager to start working with its members."

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics'SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

CONTACT: Company Contact:

         AngioDynamics, Inc.D. Joseph Gersuk, CFO

         (800) 772-6446 x1608

         Investor Relations Contacts:

         EVC Group, Inc.Doug Sherk/ Greg Gin

         (415) 568-4887; (646) 445-4801

         Media Contact:

         EVC Group, Inc.Chris Gale

         (646) 201-5431

Source: AngioDynamics

News Provided by Acquire Media